Komori
Mochida Pharmaceutical (4534) · PolicySoftened

Purpose of Strategic Shareholdings: Business Relationships and Collaboration, and Regular Reviews

First written in FY2021. 2 of 5 entries say "Restated". Latest entry: FY2026.

5entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021 – FY2022AdvancedFY2024RestatedFY20252021: 120212022: 120222023: 020232024: 120242025: 120252026: 12026
Same theme, other companies
Verification of the Rationale for Strategic ShareholdingsA theme 1245 companies write about · 1 as a headwind · 663 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1249 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026SoftenedAnnual report

    「Every year, the Board of Directors comprehensively assesses the current and future significance of each holding, including its impact on business relationships, and reviews whether each individual holding should be retained.」

    The frequency of reviews of cross-shareholdings has changed from every six months to annually.
  2. FY2025RestatedAnnual report

    「Every six months, the Board of Directors comprehensively assesses the current and future significance of each holding, including its impact on business relationships, and reviews whether each individual holding should be retained.」

    The company continues to hold cross-shareholdings to maintain and strengthen business relationships and pursue future collaboration, with the Board of Directors reviewing whether to retain each holding every six months.
  3. FY2024AdvancedAnnual report

    「Shares other than unlisted shares 9 2,601」

    The company states that it reduced its cross-shareholdings by 9 issues during the year and recorded total sale proceeds of ¥2,601 million. This is presented as a specific review of holdings based on the policy of having the Board of Directors review whether to retain each holding every six months.
  4. FY2022RestatedAnnual report

    「The company holds shares in other companies to maintain and strengthen business relationships and to collect information for considering future collaboration, among other purposes. Every six months, the Board of Directors comprehensively assesses the current and future significance of each holding, including its impact on business relationships, and reviews whether each individual holding should be retained.」

    The company has reaffirmed the purpose of its cross-shareholdings and its policy of having the Board of Directors review whether to retain each holding every six months.
  5. FY2021First statedAnnual report

    「The company holds shares in other companies to maintain and strengthen business relationships and to collect information for considering future collaboration, among other purposes. Every six months, the Board of Directors comprehensively assesses the current and future significance of each holding, including its impact on business relationships, and reviews whether each individual holding should be retained.」

    The company states that the purpose of its cross-shareholdings is to maintain and strengthen business relationships and pursue future collaboration, and that the Board of Directors reviews whether to retain each holding every six months.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Mochida Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Purpose of Strategic Shareholdings: Business Relationships and Collaboration, and Regular Reviews | Mochida Pharmaceutical Co.,Ltd. (4534) | Komori